FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Globulin topics
Immunoglobulin
Antibodies
Recombinant
Immunoglobulins
Polypeptide
Cancer Cell
Nucleic Acid
Immune Response
Monoclonal
Compatibility
Major Histocompatibility Complex
Histocompatibility
Prophylactic
Extracellular
Metastasis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Globulin patents



      
           
This page is updated frequently with new Globulin-related patent applications. Subscribe to the Globulin RSS feed to automatically get the update: related Globulin RSS feeds. RSS updates for this page: Globulin RSS RSS


Date/App# patent app List of recent Globulin-related patents
08/21/14
20140235482
 Immunoglobulin fc polypeptides patent thumbnailnew patent Immunoglobulin fc polypeptides
Methods and compositions involving polypeptides having an aglycosylated antibody fc domain. In certain embodiments, polypeptides have an aglycosylated fc domain that contains one or more substitutions compared to a native fc domain.
08/21/14
20140234961
 Synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle containing fusion proteins for targeted introduction of sirna patent thumbnailnew patent Synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle containing fusion proteins for targeted introduction of sirna
A fusion protein and process are provided by which double-stranded rna containing small interfering rna nucleotide sequences is introduced into specific cells and tissues. A cell surface receptor specific synthetic single chain variable domain (scfv) immunoglobulin fragment vehicle specific to a cell surface receptor of the cell and having a cell surface receptor specific binding site is provided.
08/21/14
20140234899
 Process for antibody g1 glycoform production patent thumbnailnew patent Process for antibody g1 glycoform production
The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with g1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.. .
08/21/14
20140234893
 Heterologous intron within an immunoglobulin domain patent thumbnailnew patent Heterologous intron within an immunoglobulin domain
The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns..
08/21/14
20140234297
 Antibody constant domain regions and uses thereof patent thumbnailnew patent Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140234294
 Fibroblast growth factor receptor-derived peptides binding to ncam patent thumbnailnew patent Fibroblast growth factor receptor-derived peptides binding to ncam
The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of ncam. The peptides are peptide fragments of fgfrs.
08/21/14
20140234293
 Combination therapy using immunoglobulin and c1-inhibitor patent thumbnailnew patent Combination therapy using immunoglobulin and c1-inhibitor
Methods are disclosed for treating cerebral ischemia using a combination of c1-inh and immunoglobulin, such as human plasma derived immunoglobulin (ivig).. .
08/21/14
20140234208
 Dual variable domain immunoglobulins and uses thereof patent thumbnailnew patent Dual variable domain immunoglobulins and uses thereof
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
08/14/14
20140227293
 Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) patent thumbnailMethod for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
The present invention provides methods and compositions for the treatment and prevention of angiogenesis, or cancer, e.g., metastatic cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (igpr-1) protein or expression. In particular, the present invention provides methods and compositions for the treatment and prevention of cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (igpr-1) protein or expression which is a soluble extracellular domain igpr-1.
08/14/14
20140227270
 Bispecific anti-cxcr7 immunoglobulin single variable domains patent thumbnailBispecific anti-cxcr7 immunoglobulin single variable domains
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting cxcr7 mediated tumour growth..
08/14/14
20140227267
Bovine fusion antibodies
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (cdr3h) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the cdr3h.
08/14/14
20140227264
Drug fusions and conjugates with extended half life
The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules.
08/07/14
20140223588
A2m fragments and applications thereof
The application relates to a polypeptide, the amino acid sequence of which is the sequence of a sub-fragment of the c-terminal thioester-cleaved fragment of human alpha-2-macroglobulin (a2m), wherein the molecular weight of said polypeptide is of 36 to 44 kda, and wherein the first n-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human a2m, is at a position 1,098 or 1,085 or 1,084 or 1,083, and the last c-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human a2m, is one of the last twenty c-terminal amino acids. This polypeptide is differently abundant depending on the stage of liver fibrosis.
08/07/14
20140221625
B cell lineage based immunogen design with humanized animals
Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in b-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design..
08/07/14
20140221613
Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g
The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an fc region of an immunoglobulin and/or the binding property to an fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein g, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody. The present invention relates to: a protein that is reduced in the binding property to an fc region of an immunoglobulin and/or the binding property to an fab region of the immunoglobulin in a weakly acidic region compared with that of a multimer comprising an extracellular domain of wild type one, which is a domain having a binding activity to a protein comprising an fc region of immunoglobulin g, while keeping a high antibody-binding activity in a neutral region, and also has a binding activity to a protein comprising the fc region of immunoglobulin g, wherein the protein comprises a tandem-type multimer of a mutant of the extracellular domain; and others..
08/07/14
20140220562
Method of predicting responsiveness of b cell lineage malignancies to active immunotherapy
Predictive biomarkers identify those patients suffering from immunoglobulin positive (ig+) b lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the cdr1 (herein termed cdr1-y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of cdr1 tyrosine residues (herein termed cdr1-yhi) is predictive of a low anti tumor response..
08/07/14
20140220019
Dual variable domain immunoglobulins and uses thereof
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
08/07/14
20140220017
Serum half-life extension using igbd
The present invention relates to complexes comprising (i) an immunoglobulin (ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the ig binding moiety specifically binds to the constant domain 1 of the heavy chain (ch1) of an ig molecule and their use for therapy and prophylaxis.. .
08/07/14
20140220015
Combinations of modalities for the treatment of diabetes
A method of treating, preventing, or delaying the progression of type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a t-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic t-lymphocyte-associated antigen 4 (ctla4) molecule and a type 1 diabetes autoantigen.
08/07/14
20140220012
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
08/07/14
20140220009
Compositions and methods for treating cocaine-related disorders
A method of treating a cocaine-related disorder in an individual is provided, the method including administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In a specific embodiment, the antibody is a monoclonal antibody comprising a murine lambda light chain variable region, a human gamma heavy chain variable region, and a human kappa or lambda light chain constant region..
08/07/14
20140219912
Dual variable domain immunoglobulins and uses thereof
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
07/31/14
20140213774
Process for obtaining immunoglobulins from colostral milk
(c) the first permeate p1 is subjected to ultrafiltration thus producing a second permeate p2 which contains lactose and minerals, and a second retentate r2, in which the immunoglobulins are concentrated.. .
07/31/14
20140213773
Adam6 mice
Mice are provided that comprise a reduction or deletion of adam6 activity from an endogenous adam6 locus, or that lack an endogenous locus encoding a mouse adam6 protein, wherein the mice comprise a sequence encoding an adam6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic adam6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating.
07/31/14
20140213772
Cross-over dual variable domain immunoglobulin constructs
Engineered cross-over dvd-ig binding proteins that bind to two or more target proteins (e.g., antigens) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
07/31/14
20140213768
Dual variable domain immunoglobulin and uses thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
07/31/14
20140212440
Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin.
07/31/14
20140212435
Rapid clearance of antigen complexes using novel antibodies
The present invention relates to immunoglobulins that bind ige and fcγriib with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored ige. Such compositions are useful for treating ige-mediated disorders, including allergies and asthma..
07/31/14
20140212416
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long hcdr3s from non-human vertebrates and cells.


Popular terms: [SEARCH]

Globulin topics: Immunoglobulin, Antibodies, Recombinant, Immunoglobulins, Polypeptide, Cancer Cell, Nucleic Acid, Immune Response, Monoclonal, Compatibility, Major Histocompatibility Complex, Histocompatibility, Prophylactic, Extracellular, Metastasis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Globulin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Globulin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2856

3595

4 - 0 - 80